Mepyramine, also known as pyrilamine, is a first-generation antihistamine, targeting the H₁ receptor as an inverse agonist. Mepyramine rapidly permeates the brain, often causing drowsiness. It is often sold as a maleate salt, pyrilamine maleate. Technically it is a tertiary amine antihistamine with sufficient lipophilicity to cross the blood brain barrier, producing both peripheral H₁ blockade and central sedative effects; the maleate counterion is used to improve crystalline properties and aqueous solubility for formulation. In pharmacology and formulation contexts note its strong H₁ selectivity relative to H₂ and H₃ sites, its utility in low-dose topical and older oral combination products, and typical physicochemical considerations for drug development such as salt selection, pKa-driven solubility, and stability under light and heat exposure.
Parent: Mepyramine / Mepyramine Maleate
Parent: Mepyramine
Typical quality specifications used for pyrilamine API batches require high assay purity and tight control of related substances: assay by validated HPLC is commonly greater than or equal to 98.0 percent. Individual unidentified related compounds are typically limited to not more than 0.5 percent each, with total impurities not to exceed 2.0 percent by area percent or mass fraction depending on the pharmacopeial method. Common related compounds observed in stability and synthetic profiles include N-oxides, N-desalkylated (desmethyl) derivatives and residual starting-material benzyl or anisyl impurities; maleate-related counterion impurities and trace residual solvents are controlled to ICH Q3C limits, and heavy metals and microbial limits follow applicable pharmacopeia. Specifications should be confirmed against the certificate of analysis for a given supplier lot.
Mepyramine is used to relieve allergic symptoms such as rhinorrhea, sneezing, nasal itching, urticaria and localized itching from insect bites; it is formulated in topical antipruritic products and in some older oral cold and allergy combination medicines. It is chosen where a rapid-onset H₁ blockade is required, recognizing its sedative liability.
Mepyramine acts as an inverse agonist at the histamine H₁ receptor, stabilizing the receptor in an inactive conformation and reducing constitutive H₁ activity in addition to preventing histamine binding.
Mepyramine binds to H₁ receptors on target cells and shifts receptor equilibrium toward the inactive state, blocking histamine-induced G protein mediated signaling that normally increases intracellular calcium and downstream inflammatory responses; central nervous system penetration produces sedation by antagonizing central H₁ receptors.
Pyrilamine maleate is found in certain topical antipruritic creams and in some legacy or regional over-the-counter cold and allergy combination products; exact brand presence varies by country and regulatory approvals, so consult local product labels or national formularies for up-to-date brand and formulation information.
